Daniel Gardner
Family · Daphne, ALNPI 1275913279
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 589 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 589 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$1K
- Genentech USA, Inc.$931
- plus $4K from 29 others
What the payments were for
- Food & beverage$12,73899%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 94 | $2,274 |
| GSK | 107 | $1,524 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $1,401 |
| Regeneron Healthcare Solutions, Inc. | 55 | $1,398 |
| Sanofi | 43 | $1,023 |
| Genentech USA, Inc. | 39 | $931 |
| CSL Behring | 27 | $710 |
| Amgen | 15 | $375 |
| Grifols USA, LLC | 12 | $269 |
| Optinose US, Inc. | 13 | $268 |
| Incyte Corporation | 11 | $240 |
| Novartis | 11 | $231 |
| Boehringer Ingelheim | 15 | $223 |
| Pfizer | 11 | $212 |
| Kaleo, Inc. | 10 | $190 |
| Biocryst US Sales Co., LLC | 8 | $188 |
| Verona Pharma, Inc. | 7 | $147 |
| Mylan Specialty L.p. | 9 | $146 |
| AbbVie | 5 | $145 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $139 |
| Axsome Therapeutics, Inc. | 2 | $113 |
| Viatris Specialty LLC | 6 | $109 |
| Lilly USA, LLC | 5 | $92 |
| Philips North America LLC | 3 | $81 |
| LEO Pharma Inc. | 4 | $75 |
| Organon | 6 | $53 |
| Aytu Biopharma, Inc. | 2 | $51 |
| Alk-abello, Inc | 3 | $48 |
| Merck | 2 | $40 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $21 |
| Phadia US Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,823 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $61,755 |
| Dupixent SyringeDupilumab | 11 | $40,283 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $22,967 |
| Spiriva RespimatTiotropium Bromide | 25 | $12,975 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,757 |
| Arnuity ElliptaFluticasone Furoate | 22 | $5,398 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,122 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $4,086 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $2,201 |
| Epinephrine | 11 | $2,181 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,894 |
| Mometasone Furoate | 16 | $1,786 |
| Montelukast Sodium | 76 | $843 |
| Azelastine Hcl | 22 | $842 |
| Fluticasone Propionate | 42 | $636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,524 | $74,910111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,274 | $28,08932 claims |
| Boehringer IngelheimSpiriva Respimat | $223 | $12,97525 claims |
| Hikma Pharmaceuticals USAEpinephrine | $29 | $2,18111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Daphne
- Nina HibbardDaphne$12K
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.